SARS-CoV-2 S1 Receptor Binding Domain (S1RBD) (expressed inHEK293 cells)
Tag: His at C-terminus
Cat. No.: 41A231
Size: 100 ug
Endotoxin: <5 EU/mg, determined by the LAL method
INTRODUCTION TO THE MOLECULE
The SARS-CoV-2 glycosylated spike (S) protein highly exposed on the viral surface is a major determinant for virus binding and invasion into hose cells, which is a main target for neutralization antibody. The receptor-binding domain (RBD) in SARS-CoV-2 S protein is responsible for binding to human and bat angiotensin-converting enzyme 2 (ACE2) receptors.
Recombinant SARS-CoV-2 Spike Protein (RBD) consists of 234 amino acids (Arg319-Phe541) with C-terminal His-tag. It has an apparent molecular mass of ~25 kDa in SDS-PAGE. The concentration of protein was determined by BCA.
BIOACTIVITY AND ANTIGENICITY
Strong binding ability with human ACE2 protein and binding capacity to a human anti-S1RBD monoclonal antibody (determined by ELISA).
FORMULATION AND RECONSTITUTION
The protein is lyophilized in PBS, PH 7.4. Add appropriate volume of PBS into the tube and let the pellet dissolve completely. For example, adding 100 ul of PBS to make a final concentration of 1 mg/ml.
Store at -80°C. Recommend to aliquot the protein into smaller quantities. Avoid repeated freeze-thaw cycles.